Open an account

Vir Biotechnology

VIR · NASDAQ

$10.74+$0.53 (+5.19%)TodayMarket closed ·
Prev close $10.21

About VIR

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 367 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Employees
367
Headquarters
San Francisco, California
Listed
Oct 11, 2019
Sector
Health Care
Industry
Biotechnology
Website
vir.bio

VIR key statistics

Market cap
1.69B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.04M
Volume
1.34M
Open price
$10.19
High today
$10.88
Low today
$10.14
52 Week high
$12.00
52 Week low
$4.82

Vir Biotechnology (VIR) at a glance

Vir Biotechnology (VIR) last traded at $10.74, with a market cap of 1.69B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.14 and $10.88. The current price is 6.0% above the day's low and 1.2% below its high.

Volume so far is 1.34M shares, below the average of 2.04M shares a day.

Over the past year Vir Biotechnology has ranged from $4.82 to $12.00, and now sits 82% of the way up that range.

Vir Biotechnology met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.47 per share against an estimate of $0.3363.

The average analyst price target is $21.19, 97.3% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $21.19
Low
$15.15
Now
$10.74
High
$31.50

VIR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 30.4% on average.

  1. Q3 FY24: reported -$1.56 per share against an estimate of -$1.06
  2. Q4 FY24: reported -$0.76 per share against an estimate of -$0.8812
  3. Q1 FY25: reported -$0.88 per share against an estimate of -$0.8441
  4. Q2 FY25: reported -$0.80 per share against an estimate of -$0.7307
  5. Q3 FY25: reported -$1.17 per share against an estimate of -$0.8622
  6. Q4 FY25: reported -$0.31 per share against an estimate of -$0.4965
  7. Q1 FY26: reported -$0.85 per share against an estimate of -$0.0964
  8. Q2 FY26: reported $0.47 per share against an estimate of $0.3363

VIR news

  • Vandana Singh

    Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

  • Press releaseBusiness Wire

    Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

  • Press releaseBusiness Wire

    Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

  • Press releaseBusiness Wire

    Vir Biotechnology Appoints David Liu as Chief Medical Officer

  • Press releaseBusiness Wire

    Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026

  • Press releaseBusiness Wire

    Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

  • Press releaseBusiness Wire

    Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

  • Press releaseBusiness Wire

    Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Similar companies

Companies in the same industry as Vir Biotechnology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.